BACKGROUND: Intrathecal Baclofen is available to treat severe generalized spasticity in Multiple Sclerosis (MS) unresponsive to oral drug delivery.
OBJECTIVE: The aims of this study were to investigate the effects and the drug dosage of intrathecal Baclofen in a selected population of MS patients, affected by severe spasticity at long term follow-up.
METHODS: A prospective cohort study of 14 MS patients is presented. Spasticity and pain were periodically assessed and the Baclofen dosage was adjusted.
RESULTS: The initial Baclofen dosage was 136.2 ± 109.3 μg, then it was increased at 12 months to 228.6 ± 179.2 μg (p < 0.05). The subsequent dose adjustments did not result in significant changes up to 76 months. Spasticity on the lower limbs decreased significantly from pre-implantation assessment (median: 3.5, IQR: 3.0–4.0) to 12 months evaluation (median: 0.5, IQR: 0.0–2.0) (p < 0.001); no further decrease was observed after 24 months (median: 0.5, IQR: 0.0–1.5); when pain was present, it decreased. Some effects on cerebellar symptoms were observed. Botulinum toxin injections were used with intrathecal Baclofen therapy.
CONCLUSIONS: A reduced spasticity and pain was observed after the intrathecal Baclofen infusion for at least 76 months. To obtain these results a dosage adjustment was needed only in the first year after the implantation.
AbelN. A., & SmithR. A. (1994). Intrathecal baclofen for treatment of intractable spinal spasticity. Arch Phys Med Rehabil, 75(1), 54–58.
2.
AshworthB. (1964). Preliminary trial of carisoprodol in multiple sclerosis. Practitioner, 192, 540–542.
3.
AzouviP., ManeM., ThiebautJ. B., DenysP., Remy-NerisO., & BusselB. (1996). Intrathecal baclofen administration for control of severe spinal spasticity: Functional improvement and long-term follow-up. Arch Phys Med Rehabil, 77(1), 35–39.
4.
Ben SmailD., PeskineA., RocheN., MailhanL., ThiébautI., & BusselB. (2006). Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients. Mult Scler, 12(1), 101–103.
5.
BohannonR. W., & SmithM. D. (1987). Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther, 67, 206–207.
6.
Brønnum-HansenH., Koch-HenriksenN., & HyllestedK. (1994). Survival of patients with multiple sclerosis in Denmark: A nationwide, long-term epidemiologic survey. Neurology, 44(10), 1901–1907.
7.
BurnsA. S., & MeythalerJ. M. (2001). Intrathecal baclefen in tetraplegia of spinal origin: Efficacy for upper extremity hypertonia. Spinal Cord, 39(8), 413–419.
CoffeyR. J., CahillD., SteersW., ParkT. S., OrdiaJ., & MeythalerJ., et al. (1993). Intrathecal baclofen for intractable spasticity of spinal origin: Results of a long-term multicenterstudy. J Neurosurg, 78(2), 226–232.
10.
DarioA., & TomeiG. (2004). A benefit-risk assessment of baclofen in severe spinal spasticity. Drug Saf, 27(11), 799–818.
11.
DoddsT. A., MartinD. P., StolovW. C., & DeyoR. A. (1993). A validation of the functional independence measurement and its performance among rehabilitation inpatients. Arch Phys Med Rehabil, 74(5), 531–536.
12.
DraulansN., VermeerschK., DegraeuweB., MeurrensT., PeersK., NuttinB., & KiekensC. (2013). Intrathecal baclofen in multiple sclerosis and spinal cord injury: complications and long-term dosage evolution. Clin Rehabil, 27(12), 1137–1143.
13.
FilippiG. M., ErricoP., SantarelliR., BagoliniB., & ManniE. (1993). Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol, 113(3), 400–404.
14.
FranciscoG. E. (2006). Successful treatment of posttraumatic hemiballismus with intrathecal baclofen therapy. Am J Phys Med Rehabil, 85(9), 779–782.
15.
Furr-StimmingE., BoyleA. M., & SchiessM. C. (2014). Spasticity and intrathecal baclofen. Semin Neurol, 34(5), 591–596.
16.
GuillameD., Van HavenberghA., VloeberghsM., VidalJ., & RoesteG. (2005). A clinical study of intrathecal baclofen using a programmable pump for intractable spasticity. ArchPhys Med Rehabil, 86(11), 2165–2171.
17.
HermanR. M., D’LuzanskyS. C., & IppolitoR. (1992). Intrathecal baclofen suppresses central pain in patients with spinal lesions. A pilot study. Clin J Pain, 8(4), 338–345.
IvanhoeC. B., TiltonA. H., & FranciscoG. E. (2001). Intrathecal baclofen therapy for spastic hypertonia. Phys Med Rehabil Clin N Am, 12(4), 923–938.
20.
J SavalA., & ChiodoA. E. (2010). Intrathecal baclofen for spasticity management: A comparative analysis of spasticity of spinal vs cortical origin. Spinal Cord Med, 33(1), 16–21.
21.
KhanA. A., Birks-AgnewI., BullockP., & RushtonD. (2010). Clinical outcome and complications of intrathecal baclofen pump in multiple sclerosis patients: A retrospective study. NeuroRehabilitation, 27(2), 117–120.
22.
KhuranaS. R., & GargD. S. (2014). Spasticity and the use of intrathecal baclofen in patients with spinal cord injury. Phys Med Rehabil Clin N Am, 25(3), 655–669.
23.
KurtzkeJ. F. (1983). Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS. Neurology, 33(11), 1444–1452.
24.
LoubsterP. G., NarayanR. K., SandinK. J., DonovanW. H., & RussellK. D. (1991). Continuous infusion of intrathecal baclofen: Long-term effects on spasticity and spinal cord injury. Paraplegia, 29(1), 48–64.
25.
MathurS. N., ChuS. K., McCormickZ., Chang ChienG. C., & MarciniakC. M. (2014). Long- term intrathecal baclofen: outcomes after more than 10 years of treatment. PM R, 6(6), 506–513.
26.
McCafferyM., Beebe, & PainA., (1989). Clinical manual for nursing practice. Mosby St. Louis, St. Louis, Missouri.
27.
McIntyreA., MaysR., MehtaS., JanzenS., TownsonA., HsiehJ., WolfeD., & TeasellR. (2014). Examining the effectiveness of intrathecal baclofen on spasticity in individuals with chronic spinal cord injury: A systematic review. J Spinal Cord Med, 37(1), 11–18.
28.
MeythalerJ. M., SteersW. D., TuelS. M., CrossL. L., & HaworthC. S. (1992). Continuous intrathecal baclofen in spinal cord spasticity. Am J Phys Med Rehabil, 71(6), 321–327.
29.
MontecuccoC., SchiavoG., & RossettoO. (1996). The mechanism of action of tetanus and botulinum neurotoxins. Arch Toxicol Suppl, 18, 342–354.
30.
O’ ConnorA. B., SchwidS. R., HerrmannD. N., MarkmanJ. D., & DworkinR. H. (2008). Pain associated with multiple sclerosis: Systematic review and proposed classification. Pain, 137(1), 96–111.
31.
PennR. D., SavoyS. M., CorcosD., LatashM., GottliebG., ParkeB., & KroinJ. S. (1989). Intrathecal baclofen for severe spinal spasticity. N Engl J Med, 320, 1517–1521.
32.
PlassatR., Perrouin VerbeB., MeneiP., MenegalliD., MathéJ. F., & RichardI. (2004). Treatment of spasticity with intrathecal Baclofen administration: long-term follow-up, review of 40 patients. Spinal Cord, 42(12), 686–693.
33.
RekandT., & GrønningM. (2011). Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up. J Rehabil Med, 43(6), 511–514.
RuniaT. F., van Pelt-GravesteijnE. D., & HintzenQ. R.
(2012). Recent gains in clinical multiple sclerosis research. CNS Neurol Disord Drug Targets, 11(5), 497–505.
36.
StampacchiaG., BradaschiaE., LenziB., CarbonciniM. C., TolainiM., AndreP., CeiG., MeucciG., & RossiB. (2004). Effect of intrathecal baclofen on cerebellar symtoms. Case Report Neurol Sci, 25, S270.
37.
ThilmannA. F., FellowsS. J., & GarmsE. (1991). The mechanism of spastic muscle hypertonus. Brain, 114(1), 233–244.
38.
WalkerH. W., LeeM. Y., BahrooL. B., HederaP., & CharlesD. (2015). Botulinum toxin injection techniques for the management of adult spasticity. PM R, 7(4), 417–427.
